Allergan Announces Plans to Build First Medical Aesthetics Innovation Center in Chengdu China
- Innovation Center to Feature State-of-the-Art Medical Aesthetics Training Center for Practitioners, Education and Experience Center for Consumers -
September 19th , 2018, Chengdu China—Allergan, a global pharmaceutical company and leader in medical aesthetics, today announced plans to open its first Medical Aesthetics Innovation Center in Chengdu China in early 2019. The center, to be located at the High-Tech Zone of Chengdu, will feature a world-class training center for medical aesthetics healthcare professionals, as well as an education and product experience center for medical aesthetics consumers.
- Allergan Expects to Train 3,000 Medical Aesthetics Practitioners Per Year Through New Center -
- Announcement Follows Recent Memorandum of Understanding Between Allergan and Chengdu Government to Co-Create China’s “Capital of Medical Aesthetics” -
- Center Expected to Open Early 2019 -
Today, at the 2018 Chengdu International Investment Summit, Allergan and the Chengdu government officially signed the cooperation agreement of the establishment of the Allergan Medical Aesthetics Innovation Center. With a total investment of more than 14.7million USD, the center is scheduled to open to the public in early 2019 and will train more than 3,000 medical aesthetics professionals every year, providing Chinese consumers with opportunities to experience Allergan’s innovative medical aesthetics products and globally-leading medical aesthetics treatments, satisfying consumer demands for a “beautiful and confident life."
Chengdu High-Tech Zone representative commented, “Following with the prosperity and development of national medical aesthetics industry, Chengdu’s medical aesthetics market has been enjoying rapidly rising demands, and increasing industrial competitiveness and influence. Our medical aesthetics market here is strengthened by our mature, sophisticated infrastructure and abundant resources for innovation. We will continue to leverage Chengdu’s geopolitical advantage as a central hub for the Belt and Road Initiative as it becomes the Capital of Medical Aesthetics, defining the medical aesthetics industry’s development. The Chengdu High-Tech Zone will always embrace international platforms with local roots like Allergan Innovation Center. Through partnered support in production, academic, and R&D, these platforms can contribute to a sustainable industrial ecology in Chengdu. Together with our partners, this strong atmosphere of innovation will help build Chengdu into China’s, and even the world’s Capital of Medical Aesthetics.”
Jason Smith, Allergan Senior Vice President and President of APAC MEA said, “Allergan’s rapid growth in China is linked to China’s growing economy, supportive government policies and growing consumer interest in medical aesthetics treatments. This strategic collaboration with Chengdu actively enables Allergan to fulfill its long-term commitment to China in the medical aesthetics field. In the future, we also plan to establish Allergan China Western Operation Center in Chengdu. We will continue working closely with the government, industry associations and medical aesthetics organizations to promote the overall development of China's medical aesthetics industry and contribute to China's economic development.”
With innovation as its driving force, Allergan has continuously introduced its leading medical aesthetics products and treatments, including Botox®, Juvederm®, and Natrelle® to China. In addition to excellent products, Allergan has also introduced the world’s leading facial rejuvenation solutions to China, such as MD CodesTM and MD ASA™, which support medical aesthetics doctors to satisfy Chinese consumers’ personalized demands for scientifically-proven and safe medical aesthetics services.
Allergan China President White Wang commented, “Allergan’s rapid growth in China is driven by our desire to serve the market by continuously introducing innovative medical aesthetics products and technologies. Our Medical Aesthetics Innovation Center will allow close collaboration with the Chengdu government to explore how to accelerate the market access of innovative medical aesthetics products.”
The innovation center will make use of Allergan’s abundant innovative resources and extensive clinical experience from around the world to improve the consultation and treatment skills of Chinese medical aesthetics professionals and their clinics’ management levels. This will drive high service standards and high-quality outcomes for consumers, unlocking new momentum for China’s medical aesthetics industry.
At present, China's medical aesthetics industry is showing explosive growth. In 2018, the scale of China’s medical aesthetics market could reach 13.6 billion USD with the average growth rate of 22.7% from 2015 to 2020. Under these circumstances, China’s medical aesthetics professionals are presently unable to meet the market demand neither in quantity nor in quality. In addition, there is a lack of professional and systematic medical aesthetics professionals training in the China market, which has become an important factor behind the scarcity of qualified professionals.
As Chinese society develops into a new era, meeting its people's increasing needs for a better life and achieving high-quality growth have become the main theme of China's economic development. The medical aesthetics industry’s growth represents this focus and is primed to reach new heights in its consumption capacity, thanks to its frequent product innovation and increased consumer appetite for personalized, experience-driven treatment. Medical aesthetics consumers have become more sophisticated in their awareness and selection of medical aesthetics services, devoting more attention to the added value of innovation on top of safe, effective products.
Since entering China in 2009, Allergan provides world-class academic exchange platforms for medical aesthetics professionals through the Allergan Medical Institution (AMI). In addition, Allergan is dedicated to improving the diagnosis and treatment skills of Chinese medical aesthetics professionals, so that Allergan products can be better leveraged in serving consumers. Following the establishment of the innovation center, Allergan will continue to join hands with a wide range of industry partners, such as medical institutions and regulatory authorities, to support seminars, international academic visits, online meetings, on-site practice and demonstrations, so as to enable more Chinese medical aesthetics professionals to master the world's leading diagnosis and treatment skills and concepts of medical aesthetics.
1: Deloitte's “China’s Medical Aesthetics Market Analysis 2017” report
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, debt reduction, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.